ZAG-101 for Type 1 Diabetes
Decades of treatment without cure
Type 1 diabetes (T1D) is a well-characterized, chronic autoimmune disease where the immune system attacks and destroys the insulin-producing beta cells in the pancreas. For decades, the standard of care has been lifelong insulin therapy to help regulate blood glucose levels in people living with T1D.
Setting a new standard for the treatment of T1D patients
Zag Bio seeks to make a meaningful impact on the lives of people impacted by Type 1 diabetes. T1D patients still have insulin-producing beta cells at the time of diagnosis or before symptom onset. Our therapeutic approach aims to preserve insulin-producing beta cells to have a transformative impact on the lives of people living with T1D.
The Facts
T1D impacts a significant number of people
T1D is one of the
fastest-growing
chronic diseases
The ultimate goal for patients is a disease-modifying therapy that can slow, halt, or even reverse disease progression.
Zag Bio Solution
Beyond insulin, toward lasting disease modification
Our lead program, ZAG-101, a first-in-class, disease-modifying therapy, is in development for people with Type 1 diabetes or at high risk of developing the disease, with the goal of restoring immune tolerance and preventing autoimmunity.
ZAG-101 has now advanced to the clinic. We initially plan to enroll patients with newly diagnosed T1D in our clinical studies of ZAG-101. Ultimately, we aim to treat earlier to prevent the onset of symptomatic disease.
By engaging the body’s natural process to restore balance to the immune system, ZAG-101 has the potential to fundamentally change the treatment paradigm for T1D.
Zag’s therapy delivers new instructions.
Our bifunctional antibodies deliver pancreatic beta-cell antigens to specialized antigen-presenting cells in the thymus, where they encounter developing immune cells.
Immune cells learn tolerance.
Developing immune cells are trained to recognize the pancreatic beta-cell antigen, generating a new population of antigen-specific regulatory T cells (Tregs).
Immune tolerance is restored at the site of disease.
Antigen-specific Tregs leave the thymus and travel to the pancreas where they restore immune tolerance and halt the autoimmune attack on beta cells, potentially preserving their ability to produce insulin.
